Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc (CPIX) Covered Calls
Cumberland Pharmaceuticals Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 0.79%, low versus the past year. CPIX's highest covered call setup is the $7.50 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 41.51% out of the money with 10 days to expiration, a 42.45% return until expiration, and a 1,549.53% theoretical annualized return. Across the setups shown, annualized returns run from 100.89% to 1,549.53% at strikes between $7.50 and $10.00, with 10 to 157 days to expiration, as of Nov 10, 2026.
Read more
Running CPIX covered calls helps you generate income from Cumberland Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CPIX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CPIX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CPIX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CPIX covered call is worth writing.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
| 2026-11-20 | 10 | 7.50 | 41.51 | 0.05 | 0.10 | 225.00 | 42.45 | 1549.53 | -0.94 | +0.12 | 150 | 0.05 |
| 2027-01-15 | 66 | 10.00 | 88.68 | 0.10 | 0.30 | 480.00 | 90.57 | 500.86 | -1.89 | +0.17 | 88 | 0.20 |
| 2027-01-15 | 66 | 7.50 | 41.51 | 0.20 | 0.65 | 240.00 | 45.28 | 250.43 | -3.77 | +0.32 | 217 | 0.45 |
| 2027-04-16 | 157 | 7.50 | 41.51 | 0.10 | 4.90 | 230.00 | 43.40 | 100.89 | -1.89 | +0.70 | 14 | 4.80 |
As of Nov 10, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank0.79% Low
- Market cap (M$)88
- 52 weeks high-36.64%
- 52 weeks low217.84%
- Analyst recommendationStrong Buy
1.00 - Target price$9.75
65.82% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-0.79
- EPS growth next 5 years—
As of Nov 13, 2026